Famitinib
- Generic Name
- Famitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O2
- CAS Number
- 1044040-56-3
- Unique Ingredient Identifier
- 768FW21J3L
- Background
Famitinib has been used in trials studying the treatment of Colorectal Cancer, Renal Cell Cancer, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, and Metastatic Renal Cell Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT02336724
- Locations
- 🇨🇳
Nanjing Bayi Hospital, Nanjing, Jiangsu, China
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT01994213
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT01829841
- Locations
- 🇨🇳
Cancer Institute and Hospital Chinese Academy of Medical Sciences, Beijing, China
A Study of Famitinib in Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 154
- Registration Number
- NCT01762293
- Locations
- 🇨🇳
Cancer center, Sun Yet-sen University, Guangzhou, Guangdong, China
🇨🇳Beijing Cancer Hospital, Peking University, Beijing, China
Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT01462474
- Locations
- 🇨🇳
Department of Medical Oncology, Cancer Center, Sun Yet-sen University, Guangzhou, Guangdong, China
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT01392235
- Locations
- 🇨🇳
Department of Medical Oncology, Cancer Center, Sun Yet-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.